In this webinar...
Transdermal Delivery Systems (TDS) adhere conveniently to the skin and deliver drug systemically for extended periods. Developing generic versions of these complex drug-device combination products can be challenging. Join Dr. Sam Raney as he discusses novel approaches championed by the FDA to streamline the development of high quality, therapeutically equivalent, generic TDS products.
- Sam Raney, PhD, Lead for Topical and Transdermal Drug Products, Office of Research and Standards, Office of Generic Drugs, FDA